- Liz Highleyman | 11 December 2015
Merck's
grazoprevir/elbasvir combination cured 93% of people with HIV and hepatitis C
co-infection, was well-tolerated and did not appear to interact with
antiretrovirals, according to final results from the C-EDGE Co-infection study
presented at ...
- Keith Alcorn | 09 December 2015
The cost of treating hepatitis C (HCV) is likely to decline
dramatically over the next decade in the United States, not because of cuts in
drug prices but because the population in ...
- Liz Highleyman | 07 December 2015
Drinking
coffee was associated with lower liver stiffness – a non-invasive measure used
to estimate liver fibrosis – in people with hepatitis B, hepatitis C and
non-alcoholic fatty liver disease (NAFLD), researchers reported ...
- Liz Highleyman | 30 November 2015
People
with hepatitis C who did not achieve sustained virological response with a
prior short course of direct-acting antiviral (DAA) therapy had a high
likelihood of being cured if treated again with sofosbuvir/ledipasvir ...
- Liz Highleyman | 26 November 2015
Response-guided
therapy using an all-oral regimen of three direct-acting antivirals cured a
majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks,
according to results from the small SODAPI pilot study, ...
- Michael Carter | 25 November 2015
The number of hepatitis C virus (HCV)-related referrals for liver transplant
has declined significantly since the introduction of HCV direct-acting
antivirals (DAAs), according to two US studies presented to the recent 2015 ...
- Michael Carter | 24 November 2015
A large proportion
of patients with chronic hepatitis C virus (HCV) infection in the UK have
co-morbidities, hazardous use of drugs and alcohol and are taking medications
that can potentially interact with HCV ...
- Liz Highleyman | 23 November 2015
A majority of people
with chronic hepatitis C and advanced fibrosis or cirrhosis showed improvement
in liver health following treatment, according to study findings presented last week at the 2015 AASLD Liver ...
- Liz Highleyman | 20 November 2015
An
all-oral combination of daclatasvir, sofosbuvir and ribavirin taken for 12 or
16 weeks led to high sustained virological response rates for people with
hard-to-treat hepatitis C virus (HCV) genotype 3 and advanced ...
- Liz Highleyman | 20 November 2015
Interferon-free
treatment with daclatasvir plus sofosbuvir, with or without ribavirin, led to
sustained virological response in a majority of people with genotype 3
hepatitis C virus (HCV) and advanced liver disease treated in ...
- Liz Highleyman | 20 November 2015
Women with chronic hepatitis B and high viral
load who were treated with tenofovir (Viread)
during pregnancy were significantly less likely to transmit hepatitis B virus
(HBV) to their babies, according to study ...
- Keith Alcorn | 18 November 2015
A combination of two experimental direct-acting antivirals developed
by AbbVie cured 93 to 97% of people with genotype 3 hepatitis C infection after
a 12-week course of treatment, Paul Kwo of Indiana ...
- Liz Highleyman | 18 November 2015
A triple combination of Gilead Sciences'
sofosbuvir/ledipasvir (Harvoni) plus
the experimental HCV protease inhibitor vedroprevir cured 96% of
treatment-experienced, genotype 1 hepatitis C patients with cirrhosis, without the
need for ribavirin, according to study ...
- Liz Highleyman | 17 November 2015
A co-formulation of sofosbuvir and the pan-genotypic HCV NS5A inhibitor
velpatasvir from Gilead Sciences produced sustained
response in 99% of people with hepatitis C virus genotypes 1, 2, 4, 5 and 6, ...
- Keith Alcorn | 17 November 2015
Re-treating with an interferon-free regimen that previously
failed to cure hepatitis C can result in success if treatment is intensified
with the addition of sofosbuvir, two studies presented at the 2015 AASLD ...
- Keith Alcorn | 17 November 2015
Around one in six people with hepatitis C in four US states
had their prescriptions for direct-acting antivirals refused by insurers, and
almost half of Medicaid recipients were denied reimbursement in 2014 ...
- Keith Alcorn | 16 November 2015
A combination of two experimental direct-acting antivirals
developed by AbbVie cured 97 to 100% of non-cirrhotic people with genotype 1
hepatitis C infection in a mid-stage phase 2 study presented this week ...
- Liz Highleyman | 16 November 2015
The nucleic acid-based polymer REP 2139, used first as
monotherapy then combined with pegylated interferon, reduced hepatitis B
surface antigen (HBsAg) levels, lowered hepatitis delta viral load and
increased anti-HBs antibody titres, according ...
- Keith Alcorn | 16 November 2015
The burden of liver cancer and cirrhosis caused by hepatitis
C is likely to continue to grow in the United States despite curative treatment
for hepatitis C, and people who have cirrhosis ...
- Liz Highleyman | 16 November 2015
An 8-week triple combination of Gilead Sciences'
sofosbuvir, velpatasvir and GS-9857 showed a high sustained response rate in a
phase 2 study of people with difficult-to-treat hepatitis C virus (HCV),
including treatment-experienced people ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...